Author

Peng-Fei Jin

h-index 5 View on Semantic Scholar

We have 3 of 29 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Sep 2026

Dissociation between humoral and multi-omic immune responses to inactivated COVID-19 vaccination in patients with pulmonary tuberculosis

Introduction Patients with pulmonary tuberculosis (PTB) may experience persistent immune dysregulation during anti-tuberculosis treatment, yet vaccine evaluation in this population has largely relied on humoral endpoints. Whether preserved antibody responses reflect coordinated systems-level immune activation after ina...

Zhi-Jie Jiang, Peng-Fei Jin, Xiao-Rui Nie et al. · Frontiers in Immunology · 0 citations

Clinical trial Open access Aug 2026

The efficacy, immunogenicity and safety of the LZ901 vaccine for herpes zoster virus in adults 40 years of age or older: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

In previously completed Phase 1 and 2 clinical trials, a recombinant gE-Fc fusion protein subunit vaccine adjuvanted with aluminum hydroxide (called LZ901) demonstrated favorable safety profiles and elicited robust immune responses. This randomized, placebo-controlled, double-blind, phase 3 trial (ChiCTR2300076253) eva...

Peng-Fei Jin, Ya-Ru Quan, Xue Gao et al. · Nature Communications · 0 citations

Open access Jul 2026

Systemic immune profiling of heterologous versus homologous boosting of COVID-19 vaccination.

Heterologous boosting with Ad5-nCoV elicited more mature B cells with higher affinity and activated more abundant immune-related pathways compared to the homologous boosting with CoronaVac, which gives insights for elaborating the systemic immune landscape of heterologous-boosting COVID-19 immunization by the novel sin...

Xu Han, Hudachuan Jiang, Hui Zheng et al. · Journal of Translational Med... · 0 citations